DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/22/21

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST. With b...

Shares of Deciphera Pharmaceuticals are (NASDAQ:DCPH) up 6% after the European Commission approved Qinlock (ripretinib) as a fourth-line treatment for gastrointestinal stromal tumors. A pivotal trial showed that the drug increased overall survival compared to best supportive care. It also mai...

Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...

– QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company de...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short selling biotechnology stocks is a dangerous game to play. However, Deciphera Pharmaceuticals (NASDAQ: DCPH ) has been a boon to the bears as DCPH stock is far below its peak price. Source: Iryna Imago / Shut...

After a setback in a late-stage cancer trial wiped off more than three-quarters of its market cap on Friday, Deciphera Pharmaceuticals (NASDAQ:DCPH) has added ~3.4% in the pre-market. The Phase 3 INTRIGUE designed to assess Qinlock as a potential treatment for a certain group of pat...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to fresh record highs Friday following a stronger than expected jobs report that showed 531,000 jobs added in October and a re...

Friday's standout performers were largely defined by their relationship to Pfizer. The drug maker announced blockbuster results from a clinical trial of its COVID pill, revealing an 89% reduction in risk for hospitalization or death. In response, travel stocks rallied, including substantial g...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Any time a stock moves down 75% over a given period of time, investors have reason to be concerned. When such a move happens in a given trading day, it’s time to ring the alarm bells. For investors in Deciphera Ph...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Deciphera Pharmaceuticals, Inc. Shares Fell 73% After its INTRIGUE Phase 3 Clinical Study Failed to Meet its Primary Endpoint” Deciphera Pharmaceuticals, I...